Latest Period
Q2 2026
Security Snapshot
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) Institutional Ownership
CUSIP: 68232V884
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
34
Shares (Excl. Options)
6,156,331
Price
$0.84
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Symbol
- TRAW on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 6,156,331
- Total 13F value
- $5,190,730
- Portfolio coverage rank
- 0%
- Share change
- +2,536,535
- Value change
- +$1,553,906
- Number of holders
- 34
- Shares outstanding
- 66,317,919
- SEC-reported price per share
- $0.44
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TRAW - Traws Pharma, Inc. - Common Stock, par value $0.01 per share is tracked under CUSIP 68232V884.
- 34 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 27 to 34 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $6,624,230 to $5,190,730.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 34 institutions filings for Q2 2026.
Security key
68232V884
Latest holder period
Q2 2026
13F holders
34
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
TRAW full holder history
Traws Pharma, Inc. SEC filings
Traws Pharma, Inc. company facts
Traws Pharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68232V884:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
TRAW
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sirenia Capital Management LP | 9.9% | $4,464,522 | 6,565,474 | Sirenia Capital Management LP | 30 Jun 2026 | |||
| ORBIMED ADVISORS LLC | 12% | -40% | $3,431,754 | +$2,040,131 | 1,876,198 | +147% | ORBIMED ADVISORS LLC | 16 Apr 2026 |
| Ikarian Capital, LLC | 9.5% | -4.9% | $1,057,688 | +$505,171 | 1,555,423 | +91% | Ikarian Capital, LLC | 30 Jun 2026 |
| PERCEPTIVE ADVISORS LLC | 6.1% | -39% | $1,793,061 | +$170,058 | 979,815 | +10% | Perceptive Advisors LLC | 31 Mar 2026 |
| Adage Capital Management, L.P. | 4.8% | -48% | $496,400 | 730,000 | 0% | Adage Capital Management, L.P. | 30 Jun 2026 | |
| Chernett Jorey | 6.8% | $668,220 | 543,268 | Chernett Jorey | 14 Jan 2026 | |||
| Ayrton Capital LLC | 4.3% | -56% | $552,125 | -$97,751 | 342,935 | -15% | Ayrton Capital LLC | 31 Dec 2025 |
| Alyeska Investment Group, L.P. | 9.9% | $462,446 | 302,252 | Alyeska Investment Group, L.P. | 31 Dec 2024 |
As of 30 Jun 2026, 34 institutional investors reported holding 6,156,331 shares of Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW). This represents 9.3% of the company’s total 66,317,919 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 6,156,331 | $5,190,730 | +$1,553,906 | $0.84 | 34 |
| 2026 Q1 | 3,619,796 | $6,624,230 | +$459,630 | $1.83 | 27 |
| 2025 Q4 | 3,418,588 | $3,863,003 | +$1,409,923 | $1.13 | 21 |
| 2025 Q3 | 1,304,595 | $2,413,244 | +$101,966 | $1.85 | 18 |
| 2025 Q2 | 1,263,487 | $1,869,962 | -$1,075,287 | $1.48 | 19 |
| 2025 Q1 | 1,732,309 | $3,984,315 | +$1,207,345 | $2.30 | 18 |
| 2024 Q4 | 1,141,975 | $10,140,752 | +$4,400,867 | $8.88 | 17 |
| 2024 Q3 | 646,356 | $3,800,574 | +$3,742,033 | $5.88 | 10 |